Silvercrest Asset Management Group LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 50,476 shares of the biopharmaceutical company’s stock after acquiring an additional 3,455 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Gilead Sciences were worth $3,805,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Archford Capital Strategies LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $106,000. Certified Advisory Corp bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $133,000. Advisors Preferred LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $140,000. Stelac Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $141,000. Finally, Mckinley Capital Management LLC Delaware raised its stake in shares of Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 860 shares in the last quarter. Hedge funds and other institutional investors own 77.71% of the company’s stock.

Gilead Sciences opened at $71.15 on Friday, Marketbeat Ratings reports. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32. The company has a market cap of $92.70 billion, a P/E ratio of 8.31, a price-to-earnings-growth ratio of -6.20 and a beta of 1.15. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.19). The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The firm’s revenue was down 21.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.23 earnings per share. equities analysts forecast that Gilead Sciences, Inc. will post 5.75 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s dividend payout ratio is 26.64%.

In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction on Friday, April 13th. The stock was sold at an average price of $75.56, for a total value of $440,741.48. Following the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,416,633.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $73.14, for a total value of $3,657,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares in the company, valued at $224,376,112.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 185,001 shares of company stock worth $13,226,824. Insiders own 1.30% of the company’s stock.

A number of brokerages have recently issued reports on GILD. Royal Bank of Canada reiterated a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, February 23rd. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a research note on Monday, February 19th. Leerink Swann reiterated a “market perform” rating and set a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Barclays reiterated an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $88.00.

Gilead Sciences Company Profile

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.